Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

Cited by (684)

Items 501–600 of 684

1. Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
   Teresa Morán, Eudald Felip, Joaquim Bosch‐Barrera, Itziar de Aguirre, José Luis Ramírez, Carles Mesía, Enric Carcereny, Diana Roa, Èlia Sais, Yolanda García García et al. · 2018 · Oncotarget
2. Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer
   Seema Nagpal, Michael T. Milano, Veronica Chiang, Scott G. Soltys, Alexandria L. Brackett, Lia Moriguchi Halasz, Amit Kumar Garg, Arjun Sahgal, Manmeet Singh Ahluwalia, Martin C. Tom et al. · 2024 · Neuro-Oncology
3. Identification of a covalent NEK7 inhibitor to alleviate NLRP3 inflammasome-driven metainflammation
   Xiangyu Jin, Yanqing Yang, Didi Liu, Xinru Zhou, Yi Huang · 2024 · Cell Communication and Signaling
4. Chemical Adaptation in Drug Discovery: The Medicinal Chemistry Journey of Olverembatinib and Limertinib in Overcoming Kinase Drug Resistance
   Ke Ding, Yupeng Li, Yang Zhou, Weixue Huang · 2025 · Accounts of Chemical Research
5. AZD9291 in TKI EGFR resistance in non-small cell lung cancer and the new concept of phase I trials.
   Ignacio Gil Bazo, Christian Diego Rolfo · 2016 · Europe PMC (PubMed Central)
6. Real-time molecular optical micro-imaging of EGFR mutations using a fluorescent erlotinib based tracer
   Maxime Patout, Florian Guisier, Xavier Brune, Pierre Bohn, Anthony Romieu, Nasrin Sarafan‐Vasseur, Richard Sesboüé, Pierre‐Yves Renard, Luc Thiberville, Mathieu Salaün · 2019 · BMC Pulmonary Medicine
7. Uncommon EGFR Mutations Conducted with Osimertinib in Patients with NSCLC: A Study Protocol of Phase 2 Study (UNICORN/TCOG1901)
   Yusuke Okuma, Mototsugu Shimokawa, Kana Hashimoto, Hideaki Mizutani, Hiroshi Wakui, Shuji Murakami, Shinji Atagi, Koichi Minato, Masahiro Seike, Yuichiro Ohe et al. · 2022 · Future Oncology
8. Kinase inhibitors for cancer alter metabolism, blood glucose, and insulin
   Brittany M. Duggan, Daniel M. Marko, Raveen Muzaffar, Darryl Y. Chan, Jonathan D. Schertzer · 2022 · Journal of Endocrinology
9. Non-Small Cell Lung Cancer – from Immunobiology to Immunotherapy
   Ondřej Bílek, Lucia Bohovicová, Regina Demlová, Alexabdr Poprach, Radek Lakomý, Lenka Zdražilová Dubská · 2016 · Klinicka onkologie
10. Detection of EGFR T790M Mutation by Droplet Digital Polymerase Chain Reaction in Lung Carcinoma Cytology Samples
    Shara Kamil Nizamaddin, Meenakshi Mehrotra, Ari Sami Hussain Nadhim, Rajyalakshmi Luthra, Sinchita Roy‐Chowdhuri · 2020 · Archives of Pathology & Laboratory Medicine
11. The Discovery of Dacomitinib, a Potent Irreversible EGFR Inhibitor
    Jessica E. Reed, Jeff Bruce Smaill · 2016 · ACS symposium series
12. Early, Goal-Directed Resuscitation for Septic Shock.
    Katja Auinger, Marco Maggiorini · 2015 · PubMed
13. The steady progress of targeted therapies, promising advances for lung cancer
    Lorenzo Bombardelli, Anton J. M. Berns · 2016 · ecancermedicalscience
14. The Impact of Genomic Profiling for Novel Cancer Therapy – Recent Progress in Non-Small Cell Lung Cancer
    Jingwu Xie, Xiaoli Zhang · 2015 · Journal of genetics and genomics/Journal of Genetics and Genomics
15. Overcoming On-Target Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
    Ibiayi Dagogo‐Jack, Jeffrey A. Engelman, Alice Tsang Shaw · 2016 · Annual Review of Cancer Biology
16. Lentivirus‐mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro
    Yaqing Li, Yuanshun Liu, Xiwang Ying, Hong‐Bin Zhou, Zhehua Wang, Shengchang Wu, Jian‐Ping Yan, Yu‐Ting Jing, Yang� Yang · 2017 · Biotechnology Progress
17. Serum microRNA-365 suppresses non-small-cell lung cancer metastasis and invasion in patients with bone metastasis of lung cancer
    Yanyan Liu, Junmei Jia, Bin Song, Haile Qiu, Gang Liang, Bo Zhang, Kang Wang · 2020 · Journal of International Medical Research
18. Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer
    Hsian-Yu Wang, Yu‐Ling Chang, Chun-Chun Cheng, Min‐Wu Chao, Su-I Lin, Shiow‐Lin Pan, Chih-Cheng Hsu, Tsang‐Wu Liu, Han-Chin Cheng, Ching‐Ping Tseng et al. · 2016 · Oncotarget
19. Lungenkrebs: EGFR‐Inhibitoren mit hoher Wirksamkeit gegen die therapieresistente L858R/T790M/C797S‐Mutante.
    Marcel Günther, Michael Juchum, Gerhard Kelter, Heiner H. Fiebig, Stefan Laufer · 2016 · Angewandte Chemie
20. Comparative efficacy and safety of first‑line PD‑1/PD‑L1 inhibitors in immunotherapy for non‑small cell lung cancer: A network meta‑analysis
    Liyan Liu, Yilong Yan, Yuqiao Wang, Ziming Li, Li Yang, Kefu Yu, Zhigang Zhao · 2025 · Oncology Letters
21. Rapidly progressive cataract formation associated with non-small-cell lung cancer therapy
    Erica Liu, Kamden R. Kopani · 2016 · Journal of Cataract & Refractive Surgery
22. The effect of TKI therapy and chemotherapy treatment delivery sequence on total progression‑free survival in patients with advanced EGFR‑mutated NSCLC
    Jie Han, Yan Xu, Yumei Zhou, Aiju Yang, Jianfeng Cui, Pengxiang Chen, Hongyu Zhao, Xingqin Zhou, Chaoyan Shen, Jinming Yu et al. · 2020 · Oncology Letters
23. Novel Pyrimido-Pyridazine Derivatives: Design, Synthesis, Anticancer Evaluation and In Silico Studies
    Priyanka Sonker, Mamata Singh, Manisha Nidhar, Vishal Prasad Sharma, Priyanka Yadav, Rashmi Singh, Biplob Koch, Ashish Kumar Tewari · 2022 · Future Medicinal Chemistry
24. Fantastic voyage: the future of cancer diagnostics
    Tilak Kumar Sundaresan, Daniel A. Haber · 2015 · The Lancet Oncology
25. Joining Forces: Improving Clinical Response to Cellular Immunotherapies with Small-Molecule Inhibitors
    Debottam Sinha, Corey Smith, Rajiv Khanna · 2020 · Trends in Molecular Medicine
26. Radiographic appearance of leptomeningeal disease in patients with EGFR-mutated non-small-cell lung carcinoma treated with tyrosine kinase inhibitors: a case series
    Ugur T. Sener, Nassim Matin, Helena Alexandra Yu, Andrew P. Lin, Jonathan T. Yang, Rachna Malani · 2019 · CNS Oncology
27. Predicting the future from the past
    Alvar G.N. Agustí · 2017 · European Respiratory Journal
28. Multisequence MRI-based radiomics nomogram for early prediction of osimertinib resistance in patients with non-small cell lung cancer brain metastases
    Xinna Lv, Ye Li, Xiaoyue Xu, Ziwei Zheng, Fang Li, Kun Fang, Yue Wang, Bing Wang, Dailun Hou · 2023 · European Journal of Radiology Open
29. Inhibition wirkstoffresistenter Mutationsvarianten der Rezeptortyrosinkinase EGFR
    Julian Engel, Christian Becker, Jonas Lategahn, Marina Keul, Julia Ketzer, Thomas Mühlenberg, Laxmikanth Kollipara, Carsten Schultz‐Fademrecht, René Peiman Zahedi, Sebastian Bauer et al. · 2016 · Angewandte Chemie
30. Pharmacogenomics in the Treatment of Lung Cancer: an Update
    Daniela Morales-Espinosa, Silvia García-Román, Niki Karachaliou, Rafael Rosell · 2015 · Pharmacogenomics
31. Postprogression Prolongation of Survival inEGFR-Mutated Lung Cancer
    David R. Gandara, Mary Weber Redman, Fred R. Hirsch · 2015 · JAMA Oncology
32. Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report
    Clara Mayo de las Casas, María González‐Cao, Santiago Viteri, Núria Jordana Ariza, Ariadna Balada‐Bel, Mónica Garzón, Cristina Teixidó, Niki Karachaliou, Daniela Morales-Espinosa, Miguel Ángel Molina‐Vila et al. · 2016 · Translational Lung Cancer Research
33. „Liquid biopsy“: Analyse molekularer Marker aus Blutproben zur Therapiesteuerung beim Lungenkarzinom
    Wolfgang Michael Brueckl, Ralph Markus Wirtz, Tobias Bertsch, Joachim Hans Ficker, Andreas Jung · 2017 · Pneumologie
34. YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFRL858R, T790M‐mutant resistance in vitro and in vivo
    Zhang Zhang, Jian Zou, Lei Yu, Jinfeng Luo, Yan Li, Zhengchao Tu, Xiaomei Ren, Hongcheng Wei, Liyan Song, Xiaoyun Lu et al. · 2018 · Cancer Medicine
35. Design, Synthesis and Antitumor Activities of Novel Quinazolinone Derivatives as Potential EGFR Inhibitors
    Jing Wang, Liwei Huang, Xi Chen, Yangchen Yuan, Juan Sun, Meng Yang · 2022 · Chemical and Pharmaceutical Bulletin
36. How to Develop Novel Treatments for EGFR -Mutant Lung Cancer
    Giuseppe Luigi Banna, Marcello Tiseo · 2015 · Future Oncology
37. Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients?
    Jordi Remón, Julie Gorham, Benjamin Besse, Jean‐Paul Sculier · 2015 · European Respiratory Journal
38. Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies
    Mary Linton B. Peters, Daniel Botelho Costa, Deepa Rangachari · 2017 · Journal of Thoracic Oncology
39. Kinase Inhibitor Drugs
    Peng Wu, Amit Choudhary · 2018 · Wiley eBooks
40. Targeting EGFR With Indole Derivatives: Recent Advances and Therapeutic Perspectives
    Tanishq Verma, Anuradha Mehra, Amit Mittal · 2026 · Chemistry & Biodiversity
41. Combination of chemotherapeutic agents and biological response modifiers (immunotherapy) in triple-negative/Her2( +) breast cancer, multiple myeloma, and non-small-cell lung cancer
    William Morse, Haroon Nawaz, Ayesha A. Choudhry · 2023 · Journal of the Egyptian National Cancer Institute
42. Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study)
    Yusuke Okuma, Shogo Nomura, Kiichiro Ninomiya, Hiroshi Gyotoku, Shuji Murakami, Yoshihito Kogure, Daijiro Harada, Kyoichi Okishio, Hiroaki Okamoto, Yasushi Goto · 2023 · Future Oncology
43. Kinase-Bench: Comprehensive Benchmarking Tools and Guidance for Achieving Selectivity in Kinase Drug Discovery
    Tian‐Hua Wei, Shuangshuang Zhou, Xiaolong Jing, Jia‐Chuan Liu, Meng Sun, Zong-Hao Zhao, Qingqing Li, Zixuan Wang, Jin Yang, Yun Zhou et al. · 2024 · Journal of Chemical Information and Modeling
44. Epidermal growth factor receptor mutations in nonsmall cell lung carcinoma patients in Kuwait
    Rabeah Abbas Al-Temaimi, Kusum Kapila, Fahd Al‐Mulla, Issam M. Francis, Salah Al-Waheeb, Bushra Al‐Ayadhy · 2016 · Journal of Cytology
45. Tyrosine kinase inhibitors in the treatment of advanced lung cancer from example of preferential medicine provision in Moscow city
    Dmitry A. Andreev, Alexander A. Zav’yalov, K. I. Polyakova, M. V. Davydovskaуa · 2020 · PULMONOLOGIYA
46. Introduction
    Harun Patel, Rahul H. Pawara, Sanjay Javerilal Surana · 2019 · Elsevier eBooks
47. Downregulation of TRIB3 enhances the sensitivity of lung cancer cells to amino acid deprivation by suppressing AKT activation
    Se Hee Ahn · 2024 · American Journal of Cancer Research
48. Les TKI de 3e génération dans le cancer pulmonaire non à petites cellules EGFR muté ayant acquis une résistance secondaire T790M
    Solenn Brosseau, Marie Viala, Andréa Varga, David Planchard, Benjamin Besse, Jean‐Charles Soria · 2015 · Bulletin du Cancer
49. Actualités sur les thérapies ciblées dans les cancers bronchiques non à petites cellules, hors immunothérapie
    Cécile Hamard, Anne-Marie Ruppert, A. Lavolé, Nathalie Rozensztajn, Martine Antoine, Jacques L. Cadranel, Marie Wislez · 2016 · Annales de Pathologie
50. Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme
    Colin R. Lindsay, Emily Clare Shaw, Fiona Helen Blackhall, Kevin G. Blyth, James D. Brenton, Anshuman Chaturvedi, Noel William Clarke, Craig Dick, T.R.J. Evans, Geoff D. Hall et al. · 2018 · ESMO Open
51. Approved and Clinical Trial Third-Generation EGFR Inhibitors
    Harun Patel, Rahul H. Pawara, Sanjay Javerilal Surana · 2019 · Elsevier eBooks
52. Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer
    Dong Ha Kim, Yun Jung Choi, Seon Ye Kim, Jungeun Lee, Ki Jung Sung, Young Hoon Sung, Sung-Eun Kim, Sung-Eun Kim, Hyung Chul Ryu, Jae Sun Kim et al. · 2018 · Targeted Oncology
53. Identification of somatic copy number variations in plasma cell free DNA correlating with intrinsic resistances to EGFR targeted therapy in T790M negative non-small cell lung cancer
    Lucheng Zhu, Jiafeng Liang, Bing Xia, Yasi Xu, Ziliang Qian, Shenglin Ma, Shirong Zhang · 2020 · Journal of Thoracic Disease
54. Understanding tumor heterogeneity: Implications for precision oncology and therapeutic strategies
    Yinchun Lv, Chenjia He, Qibing Xie, Feiwu Long, Chuanwen Fan · 2026 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
55. Investigating the antiproliferative mechanisms of NaHS, a hydrogen sulfide donor, in the SH-SY5Y cell line
    Ayşegül Öztürk, Zıad Joha, Neslihan Basgoz, Ahmet Şevki Taşkıran · 2025 · Medical Oncology
56. Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
    Marta Capelán, Desamparados Roda, Elena Geuna, Karim Rihawi, Shankar Bodla, Stan B. Kaye, Jaishree Bhosle, Udai Banerji, Mary E.R. O'Brien, Johann Sebastian De Bono et al. · 2017 · Lung Cancer
57. Indicación del tratamiento con doble antiagregación más allá del año. A quién y por qué
    Juan Carlos Gómez-Polo, David Vivas, Inmaculada Roldán · 2017 · Revista Española de Cardiología Suplementos
58. A kinetic study of thiol addition to N -phenylchloroacetamide
    Sarah K. I. Watt, Janique G. Charlebois, Christopher N. Rowley, Jeffrey W. Keillor · 2023 · Organic & Biomolecular Chemistry
59. Enhanced anticancer effect of cetuximab combined with stabilized silver ion solution in EGFR-positive lung cancer cells
    Aysun Ozkan, Ayşe Erdoğan, Ödül Özkan, Esra Manguoğlu, Nadir Kiraz · 2019 · Turkish Journal of Biochemistry
60. Complete remission through icotinib treatment in Non-small cell lung cancer epidermal growth factor receptor mutation patient with brain metastasis: A case report
    Tao Wang, Ruimin Wang, Zhouhuan Dong, Naichao Liang, Ping Chang · 2016 · Open Medicine
61. From Uniplex to Multiplex Molecular Profiling in Advanced Non–Small Cell Lung Carcinoma
    Ecaterina E. Ileana, Ignacio Ivan Wistuba, Julie G. Izzo · 2015 · The Cancer Journal
62. [Research Progress of Targeted Therapy for EGFR Gene in Non-small Cell Lung Cancer].
    Hui Zhang, Shucai Zhang · 2017 · Europe PMC (PubMed Central)
63. Continuation of Tyrosine Kinase Inhibitor is Associated with Survival Benefit in NSCLC Patients with Exon 19 Deletion after Solitary Progression
    Feifei Na, Jie Zhang, Lei Deng, Xiaojuan Zhou, Lin Zhou, Bingwen Zou, Min Yu, Yanying Li, Jianxin Xue, Yongmei Liu · 2017 · Journal of Cancer
64. Allosteric Inhibition of the Epidermal Growth Factor Receptor
    Julie K.-L. Sinclair, Wesley E. Robertson, Deepto Mozumdar, Kim Quach, Alanna Schepartz · 2021 · Biochemistry
65. Molecular Testing in Lung Cancer
    Carolyn Jane Shiau, Ming‐Sound Tsao · 2016 · Elsevier eBooks
66. The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era
    Alessia Spagnuolo, Matteo Muto, Fabio Monaco, Giuseppe Colantuoni, Cesare Gridelli · 2019 · Translational Lung Cancer Research
67. Targeting EGFR Mutation in Non-Small-Cell Lung Cancer: Challenges and Future Perspectives
    Fadi Haddad, Hampig Raphaël Kourié, Joseph Gergi Kattan · 2016 · Future Oncology
68. The peptide-Au clusters inhibit EGFR exon 19 deletion mutant non-small cell lung cancer
    Wencong Zhao, Wendi Huo, Haoran Dang, Zhongying Du, Qing Yuan, Kai Cao, Xueyun Gao · 2025 · Nano Today
69. Molecular dynamics simulations reveal a strong binding capacity of colossolactone H to the EGFR inactive conformation
    Duc Toan Truong, Kiet Ho, Chinh Tam Thai, Do Thi Mai Dung, Minh Tho Nguyen, Thi Viet Bac Phung, Minh Tho Nguyen · 2025 · Physical Chemistry Chemical Physics
70. The Pitfalls of Companion Diagnostics
    Scott A. Turner, Jason D. Peterson, Jason R. Pettus, Francine Blumental De Abreu, Christopher Ian Amos, Konstantin H. Dragnev, Gregory J. Tsongalis · 2016 · Journal of Molecular Diagnostics
71. Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment
    Lavinia Tan, Benjamin Solomon · 2017 · PET Clinics
72. Development and Validation of an LC-MS/MS Method for Quantitative Determination of EAI045, A Novel EGFR Inhibitor, in Rat Plasma
    Zixuan Chu, Mingxing Xue, Shan Xiong · 2019 · Current Pharmaceutical Analysis
73. Enhanced Efficacy of Gefitinib in Drug‐Sensitive and Drug‐Resistant Cancer Cell Lines after Arming with a Singlet Oxygen Releasing Moiety
    Kunshan Huang, Beibei Huo, Dongyao Li, Jinping Xue, Juanjuan Chen · 2020 · ChemMedChem
74. Zukünftige Aufgaben onkologischer Spitzenzentren in der Forschung
    Christoph Heining, Christof V. Kalle · 2016 · Der Onkologe
75. The use of biomarkers in the treatment of non-small cell lung cancer
    Megan Ann Baumgart, Kishan J. Pandya · 2016 · Expert Review of Precision Medicine and Drug Development
76. Perspectives on Clinical Applications of CTCs
    Rajan P. Kulkarni, Stefanie S. Jeffrey · 2016 · Current cancer research
77. Personalizing Therapy for Acquired Resistance to EGFR Kinase Inhibitors in Advanced NSCLC
    Adrian Gerold Sacher, Geoffrey R. Oxnard · 2016 · American Journal of Hematology / Oncology®
78. Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non–Small Cell Lung Cancer
    Elizabeth S. Waxman, Frank V. Fossella · 2016 · Journal of the Advanced Practitioner in Oncology
79. A Rapid and Sensitive Method for Detection of the T790M Mutation of EGFR in Plasma DNA
    Hideharu Kimura, Shingo Nishikawa, Hayato Koba, Taro Yoneda, Takashi Sone, Kazuo Kasahara · 2016 · Advances in experimental medicine and biology
80. Torsades de pointes with pseudo–T wave alternans during rociletinib therapy: A novel manifestation of a rare side effect
    Alexandra E. Teng, Michael Share, Jeffrey J. Hsu, Sarah R. Rettinger, Edward B. Garon, Jonathan Wade Goldman, Eric H. Yang, Roderick H. Tung · 2018 · HeartRhythm Case Reports
81. EGFR Mutations
    Anna Manzo, Agnese Montanino, Raffaele Costanzo, Claudia Sandomenico, Giuliano Palumbo, Clorinda Schettino, Gennaro Daniele, Alessandro Morabito, Francesco Perrone, Maria Carmela Piccirillo · 2018 · Elsevier eBooks
82. Navigating the Landscape of Molecular Testing and Targeted Treatment of Non–Small Cell Lung Cancer
    Sukhmani Kaur Padda, Robert Donald Harvey · 2016 · Journal of the Advanced Practitioner in Oncology
83. T790M and Acquired Resistance of Epidermal Growth Factor Receptor to Tyrosine Kinase Inhibitors in Patients with Lung Adenocarcinoma.
    Hanifeh Mirtavoos‐Mahyari, Azizollah Abbasi Dezfouli, Zahra Esfahani‐Monfared, Adnan Khosravi, Sharareh Seifi, Kambiz Sheikhy · 2022 · PubMed Central
84. Olmutinib Reverses Thioacetamide-Induced Cell Cycle Gene Alterations in Mice Liver and Kidney Tissues, While Wheat Germ Treatment Exhibits Limited Efficacy at Gene Level
    Seema Zargar, Tanveer A. Wani, Salman Freeh Alamery, Fatimah Yaseen · 2024 · Medicina
85. Construction and validation of a prognostic signature based on anoikis-related lncRNAs in lung adenocarcinoma
    Xiaoqi Dong, Chuan Shao, Shuguang Xu, Jinjing Tu, Wenjing Xu, Dahua Chen, Yaodong Tang · 2024 · Aging
86. Glucosylated Epigallocatechin Gallate (EGCG) Derivatives Combined with EGFR Tyrosine Kinase Inhibitor Overcome Resistance in EGFR T790M Mutant Lung Cancer
    Cheng‐Ting Zi · 2019 · Biomedical Journal of Scientific & Technical Research
87. Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients
    Marta Sesé, Rosa Somoza, Inmaculada Maestu, Maria Martín Ureste, Alfredo Sánchez, Juan Felipe Cordoba, Irene Sansano, Griselda Venturas, Santiago Ramón y Cajal, Javier Hernández‐Losa · 2019 · Oncology and Therapy
88. The TIGER is extinct! (almost)
    Aditya Pradhan · 2017 · Clinical and Experimental Ophthalmology
89. The Traditional Endomyocardial Biopsy: Opportunities to Rethink Its Role as the Gold Standard
    Amit Alam, Jane E. Wilcox, Shelley Anne Hall · 2021 · Journal of Cardiac Failure
90. Synthesis, radiolabeling, and evaluation of a 68Ga-labeled tyrosine kinase inhibitor for detecting EGFRT790M mutations in vivo
    Jiajun Xie, Weiguo Xu, Hui Deng, Xiaoai Wu, Jing Zhu · 2026 · Frontiers in Bioengineering and Biotechnology
91. Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies
    Rita Khoury, Chris Raffoul, Colette Hanna, Khalil Saleh, Annoir Shayya, Meriana Nahouli, Hady Ghanem · 2026 · International Journal of Molecular Sciences
92. Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance
    Yi Chen, Qiu-pei Liu, Si-jie Yang, Jian Ding, Xiao-Yun Lu, Hua Xie · 2026 · Acta Pharmacologica Sinica
93. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
    Zetong Ma, Changhai Lei, Shi Hu · 2023 · Elsevier eBooks
94. Design and synthesis of 2-amino-4-(trifluoromethyl)pyrimidine derivatives as potential Werner-dependent antiproliferative agents
    Chang You, Shijiao Wei, Jia Yu, Guangcan Xu, Huimin Li, Xinyu Liu, Menghan Wang, Xueling Meng, Yan Xu, Gang Yu et al. · 2025 · Molecular Diversity
95. Afatinib for the treatment of non-small cell lung cancer
    Federica Biello, Claudia Maggioni, Erika Rijavec, Carlo Genova, Giulia Barletta, Elisa Gualco, Anna Truini, Simona Coco, Maria Giovanna Dal Bello, Irene Vanni et al. · 2015 · Expert Opinion on Orphan Drugs
96. Molecular landscape of non-squamous, non-small cell carcinoma of the lung
    Mia C. Weiss, Michael J. Leukam, Victoria Meucci Villaflor · 2015 · Translational Cancer Research
97. Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?
    Zofia Piotrowska, Lecia Van Dam Sequist · 2015 · The Oncologist
98. What are the Options for Non-Small-Cell Lung Cancer Patients Post Second-Line Therapy?
    Diego Luigi Cortinovis, Stefania Canova, Paolo Bidoli · 2015 · Future Oncology
99. Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR
    Christian Becker, Sinan Öcal, Hoang Duc Nguyen, Trang Thi Phuong Phan, Marina Keul, Jeffrey R. Simard, Daniel Rauh · 2016 · ChemBioChem
100. Stratification in advanced non-small cell lung cancer: precision medicine in practice
     Odd Terje Brustugun · 2016 · Expert Review of Precision Medicine and Drug Development